Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dexrazoxane - TopoTarget

Drug Profile

Dexrazoxane - TopoTarget

Alternative Names: ADR 529; Dexrazoxane hydrochloride; ICRF 187; KDX-0811; NSC 169780; Savene; Topotect; Totect

Latest Information Update: 18 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator TopoTarget
  • Developer Cumberland Pharmaceuticals; Kissei Pharmaceutical; Onxeo SA; TopoTarget
  • Class Adjunct therapies; Chemoprotectants; Piperazines; Small molecules
  • Mechanism of Action Iron chelating agents; Type II DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Chemotherapy-induced damage
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Chemotherapy-induced damage
  • Discontinued Brain cancer

Most Recent Events

  • 24 Jun 2019 Savene® licensed to Accord Healthcare in Poland
  • 31 Dec 2018 Dexrazoxane has patent protection in USA
  • 24 Jun 2018 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top